SYBE Stock Overview
SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sybleu Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.026 |
| 52 Week High | US$0.29 |
| 52 Week Low | US$0.011 |
| Beta | 0 |
| 11 Month Change | 40.54% |
| 3 Month Change | n/a |
| 1 Year Change | -84.71% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYBE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 40.5% | 1.1% | 0.1% |
| 1Y | -84.7% | 18.8% | 24.1% |
Return vs Industry: SYBE underperformed the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: SYBE underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| SYBE volatility | |
|---|---|
| SYBE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SYBE's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine SYBE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Joseph Vaini | n/a |
SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials.
Sybleu Inc. Fundamentals Summary
| SYBE fundamental statistics | |
|---|---|
| Market cap | US$275.95k |
| Earnings (TTM) | -US$307.89k |
| Revenue (TTM) | US$11.70k |
23.6x
P/S Ratio-0.9x
P/E RatioIs SYBE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYBE income statement (TTM) | |
|---|---|
| Revenue | US$11.70k |
| Cost of Revenue | US$0 |
| Gross Profit | US$11.70k |
| Other Expenses | US$319.58k |
| Earnings | -US$307.89k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,632.19% |
| Debt/Equity Ratio | -125.3% |
How did SYBE perform over the long term?
See historical performance and comparison